Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
The second quarter should bring pivotal data for Karuna and key cardiomyopathy results for Alnylam, while Ionis's eplontersen lags in amyloidosis.
The young biotech is well placed to deliver its first pivotal win, but investor focus might lie elsewhere.
A stock market rebound created a strong finish for biopharma flotations in 2019, with four $100m-plus floats, led by Phathom Pharmaceuticals.